Viridian Therapeutics 株価情報 (NASDAQ: VRDN)

最新ニュース Viridian Therapeutics (NASDAQ:VRDN) 株価情報

Viridian Therapeutics

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics Inc

Stephens &amp; Co. analyst Jim Salera maintains Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) with a Equal-Weight and raises the price target from $13 to $14.

News

Price Target

Analyst Ratings

PTLO

Stephens & Co. Maintains Equal-Weight on Portillos, Raises Price Target to $14

PayPal Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) has made several announcements and shared its growth strategy for the upcoming years, on its investor day on Tuesday attracting mixed response from analysts.
What Happened: Among other <a href="https://www.benzinga.com/25/02/43942860/paypal-eyes-double-digit-eps-growth-by-2027-teams-up-with-verifone-jp-morgan-more">important announcements,</a> the fintech giant introduced its latest merchant product, PayPal Open, a unified platform that provides businesses with a comprehensive range of checkout solutions, including PayPal, Venmo, Fastlane, and Pay Later options.
The company also renamed Braintree to PayPal Enterprise Payments as part of its rebranding. Additionally, PayPal revealed an enhanced sales partnership with point-of-sale terminal provider Verifone.
PayPal forecasted that its non-GAAP EPS will grow by a percentage in the low teens by 2027, with a long-term growth target of 20%. Additionally, the company anticipates transaction margin dollars to rise by high single digits by 2027 and exceed 10% growth in the long run.
In a regulatory filing, PayPal announced executive vice president and CFO, Jamie Miller, has been appointed to the expanded role of chief financial and operating officer. 
SEE ALSO: <a href="https://www.benzinga.com/news/25/02/43962364/president-trump-says-inflation-is-back-claims-its-not-his-fault-but-bidens-i-had-nothing-to-do-with-it">President Trump Says, &#8216;Inflation Is Back,&#8217; Claims It&#8217;s Not His Fault But Biden&#8217;s—&#8217;I Had Nothing To Do With It&#8217;</a>
Why It Matters: PayPal posted strong fourth-quarter results with consensus beating revenue and earnings. Its investor day announcements were awaited by investors who are watching the strategic moves of the company amid competition from Apple Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) Apple Pay.
However, the announcements have received mixed reactions from analysts. Barclays analyst Ramsey El-Assal wrote in an investor note, "PayPal laid out a very compelling vision of the future, with the company set to pivot away from ‘payments' and into ‘commerce,'" reported MarketWatch. TD Cowen analyst Bryan Bergin rated the stock as &#8216;Hold&#8217; with a price target of $83. Bergin also called the fintech giant&#8217;s 2027 targets &#8216;ambitious&#8217;, as per Barrons.
Meanwhile, William Blair analyst Andrew Jeffrey suggested a cautious approach for investors citing competition from Apple Pay. He also wrote, "We have particularly low conviction that&nbsp;PayPal&nbsp;can drive a higher long-term transaction yield, creating a headwind to transaction dollar growth."
The PayPal stock soared nearly 25% over the past 12 months but declined 14.5% year-to-date, as per data from <a href="https://pro.benzinga.com/dashboard">BenzingaPro</a>.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/earnings/25/02/43958373/workday-shares-climb-after-q4-report-heres-why">Workday Shares Climb After Q4 Report: Here&#8217;s Why</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

AAPL

PYPL

As PayPal Shifts Focus From Payments To Commerce, Analysts Urge Caution Amid 'Ambitious' Plans

Avanos Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNS#NYSE">AVNS</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.40 by 7.5 percent. This is a 19.44 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $179.60 million which beat the analyst consensus estimate of $177.23 million by 1.34 percent. This is a 3.64 percent increase over sales of $173.30 million the same period last year.

Earnings

Earnings Beats

AVNS

Avanos Medical Q4 Adj $0.43 Beats $0.40 Estimate, Sales $179.60M Beat $177.23M Estimate

Guidance

Health Care

General

LNTH

Lantheus Forecasts 2025 Revenues Of $1.545B-$1.61B Vs. Consensus Of $1.605B, With Adjusted EPS Of $7.00-$7.20 Vs. $6.95 Est.

2025 Outlook
For 2025, the Company expects revenue will increase 17% to 19% compared to 2024. The Company expects diluted EPS will be in the range of $2.30 to $2.40. This outlook assumes the Kurt Geiger acquisition closes on May 1, 2025.

SHOO

Steven Madden Sees FY2025 Adj EPS $2.30-$2.40 vs $2.58 Est; Sees Sales $2.658B-$2.703B vs $2.34B Est

Dividends

AerCap Holdings Raises Dividend From $0.25 To $0.27 Per Share

Needham analyst David Saxon reiterates RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) with a Buy and maintains $43 price target.

Reiteration

RXST

Needham Reiterates Buy on RxSight, Maintains $43 Price Target

INVZ

Innoviz Technologies Q4 2024 GAAP EPS $(0.11) Beats $(0.14) Estimate, Sales $6.027M Beat $5.860M Estimate

Earnings Misses

ZVIA

Zevia Q4 2024 GAAP EPS $(0.09) Misses $(0.06) Estimate, Sales $39.458M Beat $39.390M Estimate

Immunocore Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.24) by 95.83 percent. This is a 17.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $84.05 million which beat the analyst consensus estimate of $83.55 million by 0.60 percent. This is a 19.80 percent increase over sales of $70.16 million the same period last year.

IMCR

Immunocore Hldgs Q4 EPS $(0.47) Misses $(0.24) Estimate, Sales $84.05M Beat $83.55M Estimate

Astec Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTE#NASDAQ">ASTE</a>) reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $0.73 by 63.01 percent. This is a 32.22 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $359.00 million which missed the analyst consensus estimate of $371.40 million by 3.34 percent. This is a 6.47 percent increase over sales of $337.20 million the same period last year.

ASTE

Astec Industries Q4 2024 Adj EPS $1.19 Beats $0.73 Estimate, Sales $359.00M Miss $371.40M Estimate

Buybacks

AerCap Holdings Announces $1B Share Buyback Program

Barclays analyst Gaurav Jain maintains Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) with a Overweight and raises the price target from $145 to $175.

Barclays Maintains Overweight on Philip Morris Intl, Raises Price Target to $175

OPCH

Option Care Health Sees FY25 Revenue $5.3B-$5.5B vs $5.262B Est., Adj. EPS $1.59-$1.69 vs $1.25 Est., Adj. EBITDA $450M-$470M.

Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.36 by 5.56 percent. This is a 49.33 percent decrease over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $972.00 million which missed the analyst consensus estimate of $1.08 billion by 10.24 percent. This is a 18.59 percent decrease over sales of $1.19 billion the same period last year.

BLMN

Bloomin Brands Q4 2024 Adj EPS $0.38 Beats $0.36 Estimate, Sales $972.00M Miss $1.08B Estimate

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Ryvyl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) from Neutral to Neutral.

RVYL

HC Wainwright & Co. Reiterates Neutral on Ryvylto Neutral

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported quarterly earnings of $1.59 per share which beat the analyst consensus estimate of $1.53 by 3.92 percent. This is a 9.14 percent decrease over earnings of $1.75 per share from the same period last year. The company reported quarterly sales of $391.10 million which beat the analyst consensus estimate of $375.43 million by 4.17 percent. This is a 10.48 percent increase over sales of $354.00 million the same period last year.

Lantheus Holdings Q4 2024 Adj EPS $1.59 Beats $1.53 Estimate, Sales $391.10M Beat $375.43M Estimate

Bentley Systems Q4 2024 Adj. EPS $0.21 Misses $0.22 Estimate, Sales $349.822M Miss $350.361M Estimate

Analysts' ratings for Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.6, with a high estimate of $20.00 and a low estimate of $19.00. This current average reflects an increase of 3.16% from the previous average price target of $19.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740571253_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Arcutis Biotherapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcutis Biotherapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Arcutis Biotherapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Arcutis Biotherapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Arcutis Biotherapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARQT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Arcutis Biotherapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Arcutis Biotherapeutics</h2>
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
<h3>Arcutis Biotherapeutics's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Arcutis Biotherapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 17.44%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Arcutis Biotherapeutics's net margin excels beyond industry benchmarks, reaching -92.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Arcutis Biotherapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -24.21%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Arcutis Biotherapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.42%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Arcutis Biotherapeutics's debt-to-equity ratio surpasses industry norms, standing at 1.33. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARQT

A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts

Space exploration company Intuitive Machines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) is gearing up for its second moon landing attempt on Wednesday, with the anticipation sending its stock higher in after-hours trading. 
What happened: The Houston-based firm, which made history last year by becoming the first private company to touchdown on the moon, <a href="https://in.benzinga.com/general/space/25/02/43854983/im-2-launch-on-track-for-next-week-whats-going-on-with-intuitive-machines-stock-thursday">prepares to land its Nova-C lunar lander</a> near the lunar south pole.
Interestingly, the lunar lander, part of Intuitive Machines' historic expedition last year, has an old connection with Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), the world's largest meme cryptocurrency.
DOGE-1 <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21599868/dogecoin-spacex-to-the-moon-mission-will-involve-selling-space-art-as-nfts">was a satellite mission</a> by Elon Musk's space company, Space X, paid for entirely with the meme coin.&nbsp;
The satellite was supposed to go as a rideshare on the Nova-C/IM-1 mission, with Intuitive Machines talking about "taking Dogecoin to the Moon" in a post dated May 11, 2021.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We knew <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@ElonMusk</a> was taking <a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> to the Moon, but had no idea it would be on our flight. &#8211; First Commercial Lander to the Moon <a href="https://t.co/UuqQ3pJl8U">https://t.co/UuqQ3pJl8U</a>
&mdash; Intuitive Machines (@Int_Machines) <a href="https://twitter.com/Int_Machines/status/1391843506193326092?ref_src=twsrc%5Etfw">May 10, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/02/43931332/peter-schiff-questions-michael-saylor-led-strategys-leverage-bitcoin-play-amid-share-price-decline-massive-dilution-has-destroyed-shareholder-value">Peter Schiff Questions Michael Saylor-Led Strategy&#8217;s Leverage Bitcoin Play Amid MSTR Decline: &#8216;Massive Dilution Has Destroyed Shareholder Value&#8217;</a>
As things turned out, the satellite missed the planned rideshare with the IM-1 mission and was subsequently postponed. Regardless, the association produced significant hype for both the company and Dogecoin. 
Intuitive Machines went public in February 2023. So, if you had invested $1000 in both the company's stock and the meme coin exactly two years ago, Dogecoin would have netted you a return of 158%, while the LUNR stock would have trimmed your investment by 35.83%.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Assets</td>
<td>Price (Recorded on Feb. 26, 2023)</td>
<td>Investment</td>
<td>Price (Recorded on Feb. 26 at 2:30 a.m. ET)</td>
<td>Value Of Investments Today</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>LUNR Stock</td>
<td>$24.00</td>
<td>$1000</td>
<td>$15.40</td>
<td>$641.66</td>
<td>-35.83%</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>$0.08078</td>
<td>$1000</td>
<td>$0.2092</td>
<td>$2589.74</td>
<td>+158.975%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: Shares of LUNR surged 6.30% in after-hours trading, after closing 9.25% lower at $15.40 during Tuesday's regular session, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. The stock has a <a href="https://www.benzinga.com/quote/LUNR/analyst-ratings">consensus price target </a>of $15.83 based on 6 analyst ratings.&nbsp;
As of this writing, Dogecoin traded at $0.2101, up 2.84% in the last 24 hours.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43931639/riot-platforms-ceo-reaffirms-plan-to-boost-bitcoin-yield-but-not-looking-too-closely-at-strategys-maneuvers">Riot Platforms CEO Reaffirms Plan To Boost Bitcoin Yield But &#8216;Not Looking Too Closely&#8217; At Michael Saylor-Led Strategy&#8217;s Maneuvers</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

LUNR

If You Invested $1000 Each In Intuitive Machines' LUNR Stock And Dogecoin Exactly Two Years Ago, This Asset Would Have Been The Winner

Press Releases

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Comments

Viridian Therapeutics

ニュース

最新ニュース Viridian Therapeutics (NASDAQ:VRDN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル